Raymond James Financial’s Amneal Pharmaceuticals AMRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$17.6M Buy
874,367
+97,099
+12% +$1.75M ﹤0.01% 1646
2026
Q2
$13.5M Buy
777,268
+43,225
+6% +$592K ﹤0.01% 1885
2026
Q1
$9.12M Buy
734,043
+35,983
+5% +$483K ﹤0.01% 2099
2025
Q4
$8.8M Sell
698,060
-44,350
-6% -$507K ﹤0.01% 2082
2025
Q3
$7.43M Buy
742,410
+28,078
+4% +$252K ﹤0.01% 2159
2025
Q2
$5.78M Buy
714,332
+117,830
+20% +$888K ﹤0.01% 2273
2025
Q1
$5M Buy
596,502
+224,506
+60% +$1.87M ﹤0.01% 2326
2024
Q4
$2.95M Buy
+371,996
New +$3.12M ﹤0.01% 2688

Other funds holding AMRX

Raymond James Financial's AMRX Position: Q3 2026 in Review

Raymond James Financial increased its Amneal Pharmaceuticals (AMRX) stake by 12% in Q3 2026, buying an estimated $1.75M and bringing the position to 874,367 shares worth $17.6M. The position accounts for ﹤0.01% of the portfolio, ranked #1646.

Raymond James Financial first reported a position in AMRX in Q4 2024 and has held it in 8 quarters since. 334 funds tracked by Wall St. Rank hold AMRX as of Q3 2026.

  • Raymond James Financial held 874,367 shares of Amneal Pharmaceuticals worth $17.6M as of Q3 2026.
  • Raymond James Financial bought 97,099 Amneal Pharmaceuticals shares in Q3 2026, an estimated $1.75M.
  • Amneal Pharmaceuticals made up ﹤0.01% of Raymond James Financial's portfolio in Q3 2026, its #1646 holding.
  • Raymond James Financial first reported a position in Amneal Pharmaceuticals in Q4 2024 and has held it in 8 quarters since.
  • 334 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q3 2026.

Based on Raymond James Financial's 13F filing for Q3 2026, filed 12 Nov 2026.